Abstract:Liver fibrosis is a key process in the progression of chronic liver disease to cirrhosis. Currently, early diagnosis and precise staging of liver fibrosis remain great challenges. Extracellular matrix (ECM) molecules expressed specifically during liver fibrosis are ideal targets for bioimaging and detection of liver fibrosis. Here, we report that fluorescent probes based on a nucleic acid aptamer (ZY-1) targeting cellular fibronectin (cFN), a critical ECM molecule significantly accumulating during liver fibrosis, are promising bioimaging agents for the staging of liver fibrosis. In the work, the outstanding binding affinity of ZY-1 to cFN was validated through an in vitro model of human-derived hepatic stellate cells (HSCs). Subsequently, we constructed different ZY-1-based fluorescent probes and explored the real-time imaging performance of these fluorescent probes in CCl 4 -induced mouse models of different liver fibrosis stages. The ZY-1-based fluorescent probes, for the first time, effectively identified and distinguished early-stage liver fibrosis (stage 3 of Ishak 6) from advanced liver fibrosis (stage 5 of Ishak 6). The proof-of-concept study provides compelling evidences that ZY-1-based probes are a promising tool for the early diagnosis and staging of liver fibrosis and paves the way for further development of clinical-related diagnosis strategies for fibrotic diseases of the liver and other organs. Statement of significance Currently, early diagnosis and accurate staging of liver fibrosis continue to present significant challenges. This study demonstrates that fluorescent probes based on the nucleic acid aptamer ZY-1, which targets cellular fibronectin (cFN)—a crucial extracellular matrix (ECM) molecule that significantly accumulates during liver fibrosis—are promising bioimaging agents for staging liver fibrosis. The ZY-1-based fluorescent probes effectively identified and differentiated early-stage liver fibrosis from advanced liver fibrosis. This proof-of-concept study not only provides compelling evidence that ZY-1-based probes show promise for the early diagnosis and staging of liver fibrosis but also paves the way for further investigations into the use of ZY-1 in detecting other diseases associated with cFN.

Diagnosis of Liver Fibrosis: Harnessing X‐Ray Energy‐Dependent Attenuation of Bismuth‐Based Nanoprobes for Accurate Diagnosis of Liver Fibrosis (adv. Sci. 11/2021)

Recent advances in molecular magnetic resonance imaging of liver fibrosis.

Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles

Novel Strategy for Validating the Existence and Mechanism of the "gut-liver axis" in Vivo by a Hypoxia-Sensitive NIR Fluorescent Probe.

Advancements of non‐invasive imaging technologies for the diagnosis and staging of liver fibrosis: Present and future

Assessment of Liver Fibrosis Using Pharmacokinetic Parameters of Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Diffusion-weighted Imaging and Variable Flip Angle T1 Mapping: a Supplement for Image-Guided Biopsy in Follow-Up Analysis of Liver Fibrosis

Synthesis and Application of Strawberry-Like Fe3O4-Au Nanoparticles As CT-MR Dual-Modality Contrast Agents in Accurate Detection of the Progressive Liver Disease.

A FAPα-activated MRI nanoprobe for precise grading diagnosis of clinical liver fibrosis

Functional Pitch of A Liver: Fatty Liver Disease Diagnosis with Photoacoustic Spectrum Analysis

Heterogeneous Iron Oxide/Dysprosium Oxide Nanoparticles Target Liver for Precise Magnetic Resonance Imaging of Liver Fibrosis

[Functional MR Study of Hepatic Fibrosis].

Determination of Hepatic Iron Deposition in Drug-Induced Liver Fibrosis in Rats by Confocal Micro-XRF Spectrometry

A hyaluronic acid-derived imaging probe for enhanced imaging and accurate staging of liver fibrosis

Cellular fibronectin-targeted fluorescent aptamer probes for early detection and staging of liver fibrosis

Nanotechnology in Drug Delivery for Liver Fibrosis.

A novel alternative strategy for monitoring and insight into liver fibrosis progression: The combination of surface-enhanced Raman spectroscopy (SERS) and gut microbiota

Plasma biomarker screening for liver fibrosis with the N-terminal isotope tagging strategy

A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging

MRI quantification of liver fibrosis using diamagnetic susceptibility: An ex-vivo feasibility study

An activatable near-infrared molecular reporter for fluoro-photoacoustic imaging of liver fibrosis